NMTC Stock Overview

First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue

Company to Provide Overview of Business Model and Expected Revenue Acceleration in Fiscal Year 2025 EDEN PRAIRIE, Minn., Jan. 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it will hold a virtual roadshow webinar to discuss its business operations and recent updates.

Company's Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly

NeuroOne is a commercial stage medical device company with FDA-cleared electrodes used in prominent U.S. medical centers for epilepsy diagnosis and treatment. NMTC is partnered with Zimmer Biomet, a $21 billion medical device company, and is close to reaching cash flow break even, reducing shareholder dilution. NMTC's electrodes are superior due to their ability to provide real-time, high-resolution brain signal recordings and stimulate brain tissue, aiding in precise neurosurgical procedures.

License Provides Exclusive Commercialization Rights for US Distribution and Certain OUS MarketsAgreement expected to boost NeuroOne sales revenue and profitability

Forty-four ablations performed successfully in one patient Patient currently reportedly seizure free with improvements in mood and memory EDEN PRAIRIE, Minn., Sept. 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the OneRF Ablation System was recently used in a breakthrough patient procedure at the University Hospitals in Cleveland to successfully complete forty four ablations in one patient.

EDEN PRAIRIE, Minn., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on August 14, 2024, at 4:30 PM Eastern Time to discuss financial results for its third quarter of fiscal year 2024 ended June 30, 2024, and provide a corporate update.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will hold its Q2 2024 Earnings Conference Call on May 14, 2024 at 4:30 PM ET. Presenting will be Dave Rosa, President & CEO, and Ron McClurg, CFO. Welcome to the NeuroOne Medical Technologies Corporation Second Quarter of Fiscal Year 2024 Financial Results Conference Call.

NeuroOne Medical Technologies Corporation (NMTC) Q1 2024 Earnings Call Transcript